期刊
CHEST
卷 131, 期 3, 页码 897-899出版社
ELSEVIER
DOI: 10.1378/chest.06-2101
关键词
clinical trial; pulmonary fibrosis; pulmonary hypertension; sildenafil; therapeutics
资金
- NHLBI NIH HHS [P50 HL067665, 5U10HL080411, 5P50HL67665, U10 HL080411, U10 HL080411-02] Funding Source: Medline
Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis OF), and is associated with increased morbidity and mortality. Therapy with silderrafil has been shown to decrease pulmonary vascular resistance in patients with pulmonary fibrosis and may improve functional status. Patients with IPF and documented pulmonary hypertension were followed up in an open-label study of sildenafil. The 6-min walk test distance (6MWD) was obtained before and after 3 months of sildenafil therapy. Four-teen patients were followed up in the study; 11 patients completed both 6-min walk tests. The mean improvement in walk distance was 49.0 in (90% confidence interval, 17.5 to 84.0 m). When all 14 patients were dichotomized into groups of responders (ie, >= 20% improvement in 6MWD) or nonresponders (ie, < 20% change or unable to complete), 57% were classified as responders. Sildenafil is a promising and well-tolerated therapeutic agent for use in patients with IPF and pulmonary hypertension, and should be studied in a large, well-controlled trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据